CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively
low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic …

MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on
normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

Daratumumab, a human CD38 imunoglobulin G 1κ monoclonal antibody, has demonstrated
clinical activity and a manageable safety profile in monotherapy and combination therapy …

This phase 1b, open-label, dose-escalation study assessed the safety, efficacy, and
pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given in 2 schedules (3, 5 …

This phase 2 study evaluated isatuximab as monotherapy or combined with dexamethasone
in relapsed/refractory multiple myeloma (RRMM). Patients had RRMM refractory to an …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

The practice of choosing the next best therapy for patients with relapsed and/or refractory
multiple myeloma (RRMM) is becoming increasingly complex. There is no clear consensus …

The therapeutic landscape of multiple myeloma (MM) has evolved spectacularly over the
past decade with the discovery and validation of proteasome inhibitors and …

Antibodies targeting CD38 are rapidly changing the treatment landscape of multiple
myeloma (MM). CD38− directed antibodies have several mechanisms of action. Fc …